However dapagliflozin has other unique effects on the CV system which will impact on LVH. Dapagliflozin reduces blood pressure (LV afterload) and this by itself should also further reduce LVH. Further reducing BP even in normotensive patients has been shown to definitely regress LVH. Dapagliflozin also has diuretic effects which should reduce preload on the heart (this will be measured preload in this trial by MRI assessed end diastolic volume). The fact that dapagliflozin reduces both preload and afterload on the heart makes it uniquely promising as a way to reducing future CV events in patients with diabetes and, here, in reducing LV hypertrophy. Thus, dapagliflozin should regress LVH in patients with diabetes because it is unique in reducing the four main causes of LVH: glycaemia/insulin resistance, weight, preload and blood pressure. No other anti-diabetic medication alters even three of these. Even metformin only alters two since it does not change blood pressure. All other diabetic medications only reduce one (glycaemia) of these mediators of LVH. This may be why other new anti-glycaemic agents have failed to reduce CV events. In this trial, it is proposed to trial whether dapagliflozin causes regression of the independent cardiac risk factor of LVH in diabetic participants on optimal current evidence based therapy.